We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HCA Healthcare Trades at a Premium: Buy, Hold, or Avoid the Stock?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"HCA trades at 14.67X forward P/E, above its median and industry average.\",\"1\":\"Free cash flow rose 29.3% to $7.3B, fueling buybacks and dividends.\",\"2\":\"Earnings are projected to grow 18.9% in 2025 and 7.1% in 2026.\"}
U.S. hospital operator HCA Healthcare, Inc. (HCA - Free Report) is currently trading at a noticeable premium compared with its historical and industry benchmarks. The stock’s forward 12-month price-to-earnings (P/E) ratio stands at 14.67X, ahead of its five-year median of 13.91X and well above the broader industry average of 13.31X. By comparison, Universal Health Services, Inc. (UHS - Free Report) trades at 8.87X and Tenet Healthcare Corporation (THC - Free Report) at 11.73X.
This valuation gap underscores the need to examine whether HCA’s fundamentals and growth prospects justify paying a higher price.
Image Source: Zacks Investment Research
HCA’s Financial Position
At the close of the second quarter, HCA held $939 million in cash and equivalents, a sharp 51.4% decline from year-end 2024. Meanwhile, its long-term debt (excluding issuance costs and discounts) rose to $39.4 billion. A high debt level induces a rise in interest expenses, which escalated 9.5% year over year in the first half of 2025.
Nevertheless, HCA’s strong cash-generating abilities are expected to improve its financial position. Over the trailing 12 months, free cash flow totaled $7.3 billion, reflecting 29.3% growth from the prior year and building on a 20.3% rise in 2024. Such consistent growth provides the company with ample flexibility to fund acquisitions, reduce leverage and deliver shareholder returns.
Capital deployment has been aggressive. HCA repurchased $3.8 billion in shares in 2023 and $6 billion in 2024, followed by another $5 billion in the first half of 2025. Dividend payouts reached $351 million during the same period. As of June 30, 2025, the company still had $5.8 billion remaining under its existing repurchase authorization.
HCA’s Price Performance
HCA Healthcare shares have surged 34.3% so far this year, outperforming the industry average of 27.3% and the S&P 500 Index’s gain of 13.5%. While Universal Health Services has managed only a 5.7% increase, Tenet Healthcare has surged ahead with a 48% rise, reflecting robust momentum due to rising demand.
HCA YTD Performance vs. UHS, THC & S&P 500
Image Source: Zacks Investment Research
HCA’s Growth Drivers
HCA Healthcare continues to benefit from rising admissions and the breadth of its healthcare offerings across the United States. In the first half of 2025, same-facility equivalent admissions rose 2.2% year over year, while revenue per equivalent admission climbed 3.5%. The company’s surgery centers have seen a pickup in activity, with occupancy improving from 72.7% in 2024 to an average of 74.5% this year so far.
To meet growing demand, HCA has committed to strengthening its infrastructure, investing in clinical systems, digital upgrades and modernized care models. These investments are designed not only to support higher patient volumes but also to improve efficiency and outcomes, reinforcing its long-term growth trajectory.
HCA’s Earnings Estimates & Surprise History
The Zacks Consensus Estimate for HCA Healthcare’s 2025 earnings is pegged at $26.11 per share, indicating 18.9% year-over-year growth. The same for 2026 signals a further 7.1% increase. The estimates have remained stable over the past week. Also, the consensus mark for HCA’s 2025 and 2026 revenues suggests 6.1% and 4.4% year-over-year growth, respectively.
The company beat earnings estimates in each of the past four quarters with an average surprise of more than 7%.
HCA Healthcare, Inc. Price, Consensus and EPS Surprise
Despite its strengths, HCA faces notable challenges. The U.S. healthcare sector remains vulnerable to regulatory shifts and reimbursement pressure from the current administration. The growing shift toward home-based services will likely challenge hospital-centric operations in the future, potentially diluting patient volumes in traditional facilities.
Some operational metrics have shown signs of strain. Outpatient surgery cases declined 1.9% in 2024 and fell another 1.3% in the first half of 2025. For the full year, we expect a 1.5% year-over-year decline in the metric. Average length of stay has also contracted steadily, down 2.8% in 2023, 1.6% in 2024 and 1.2% so far in 2025.
Bottom Line
HCA Healthcare’s solid earnings outlook, consistent cash flow generation and shareholder-friendly capital deployment highlight its strength as a leading hospital operator. However, the stock’s elevated valuation, mounting debt burden and regulatory environment temper the bullish case. While long-term growth investments support stability, near-term risks suggest limited upside at current levels.
Image: Bigstock
HCA Healthcare Trades at a Premium: Buy, Hold, or Avoid the Stock?
Key Takeaways
U.S. hospital operator HCA Healthcare, Inc. (HCA - Free Report) is currently trading at a noticeable premium compared with its historical and industry benchmarks. The stock’s forward 12-month price-to-earnings (P/E) ratio stands at 14.67X, ahead of its five-year median of 13.91X and well above the broader industry average of 13.31X. By comparison, Universal Health Services, Inc. (UHS - Free Report) trades at 8.87X and Tenet Healthcare Corporation (THC - Free Report) at 11.73X.
This valuation gap underscores the need to examine whether HCA’s fundamentals and growth prospects justify paying a higher price.
HCA’s Financial Position
At the close of the second quarter, HCA held $939 million in cash and equivalents, a sharp 51.4% decline from year-end 2024. Meanwhile, its long-term debt (excluding issuance costs and discounts) rose to $39.4 billion. A high debt level induces a rise in interest expenses, which escalated 9.5% year over year in the first half of 2025.
Nevertheless, HCA’s strong cash-generating abilities are expected to improve its financial position. Over the trailing 12 months, free cash flow totaled $7.3 billion, reflecting 29.3% growth from the prior year and building on a 20.3% rise in 2024. Such consistent growth provides the company with ample flexibility to fund acquisitions, reduce leverage and deliver shareholder returns.
Capital deployment has been aggressive. HCA repurchased $3.8 billion in shares in 2023 and $6 billion in 2024, followed by another $5 billion in the first half of 2025. Dividend payouts reached $351 million during the same period. As of June 30, 2025, the company still had $5.8 billion remaining under its existing repurchase authorization.
HCA’s Price Performance
HCA Healthcare shares have surged 34.3% so far this year, outperforming the industry average of 27.3% and the S&P 500 Index’s gain of 13.5%. While Universal Health Services has managed only a 5.7% increase, Tenet Healthcare has surged ahead with a 48% rise, reflecting robust momentum due to rising demand.
HCA YTD Performance vs. UHS, THC & S&P 500
HCA’s Growth Drivers
HCA Healthcare continues to benefit from rising admissions and the breadth of its healthcare offerings across the United States. In the first half of 2025, same-facility equivalent admissions rose 2.2% year over year, while revenue per equivalent admission climbed 3.5%. The company’s surgery centers have seen a pickup in activity, with occupancy improving from 72.7% in 2024 to an average of 74.5% this year so far.
To meet growing demand, HCA has committed to strengthening its infrastructure, investing in clinical systems, digital upgrades and modernized care models. These investments are designed not only to support higher patient volumes but also to improve efficiency and outcomes, reinforcing its long-term growth trajectory.
HCA’s Earnings Estimates & Surprise History
The Zacks Consensus Estimate for HCA Healthcare’s 2025 earnings is pegged at $26.11 per share, indicating 18.9% year-over-year growth. The same for 2026 signals a further 7.1% increase. The estimates have remained stable over the past week. Also, the consensus mark for HCA’s 2025 and 2026 revenues suggests 6.1% and 4.4% year-over-year growth, respectively.
The company beat earnings estimates in each of the past four quarters with an average surprise of more than 7%.
HCA Healthcare, Inc. Price, Consensus and EPS Surprise
HCA Healthcare, Inc. price-consensus-eps-surprise-chart | HCA Healthcare, Inc. Quote
HCA’s Headwinds
Despite its strengths, HCA faces notable challenges. The U.S. healthcare sector remains vulnerable to regulatory shifts and reimbursement pressure from the current administration. The growing shift toward home-based services will likely challenge hospital-centric operations in the future, potentially diluting patient volumes in traditional facilities.
Some operational metrics have shown signs of strain. Outpatient surgery cases declined 1.9% in 2024 and fell another 1.3% in the first half of 2025. For the full year, we expect a 1.5% year-over-year decline in the metric. Average length of stay has also contracted steadily, down 2.8% in 2023, 1.6% in 2024 and 1.2% so far in 2025.
Bottom Line
HCA Healthcare’s solid earnings outlook, consistent cash flow generation and shareholder-friendly capital deployment highlight its strength as a leading hospital operator. However, the stock’s elevated valuation, mounting debt burden and regulatory environment temper the bullish case. While long-term growth investments support stability, near-term risks suggest limited upside at current levels.
Considering these factors, HCA currently carries a Zacks Rank #3 (Hold), implying the stock is best suited for investors looking to maintain existing positions rather than initiate new ones. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.